Agios Pharmaceuticals Inc
NASDAQ:AGIO

Watchlist Manager
Agios Pharmaceuticals Inc Logo
Agios Pharmaceuticals Inc
NASDAQ:AGIO
Watchlist
Price: 35.42 USD -1.09% Market Closed
Market Cap: 2B USD
Have any thoughts about
Agios Pharmaceuticals Inc?
Write Note

Wall Street
Price Targets

AGIO Price Targets Summary
Agios Pharmaceuticals Inc

Wall Street analysts forecast AGIO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AGIO is 56.1 USD with a low forecast of 51.51 USD and a high forecast of 59.85 USD.

Lowest
Price Target
51.51 USD
45% Upside
Average
Price Target
56.1 USD
58% Upside
Highest
Price Target
59.85 USD
69% Upside

AGIO Last Price Targets
Agios Pharmaceuticals Inc

The latest public price target was made on Oct 31, 2024 by Danielle Brill from Raymond James , who expects AGIO stock to rise by 44% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Danielle Brill
Raymond James
51 USD
Upside 44%
1 month ago
Oct 31, 2024
Raymond James Reiterates Outperform Rating on Agios Pharma (AGIO)
StreetInsider
Andrew Berens
Leerink Partners
56 USD
Upside 58%
2 months ago
Sep 27, 2024
Leerink Partners Downgrades Agios Pharma (AGIO) to Market Perform
StreetInsider
Chris Raymond
Raymond James
56 USD
Upside 58%
3 months ago
Sep 10, 2024
Piper Sandler Reiterates Overweight Rating on Agios Pharma (AGIO)
StreetInsider
Chris Raymond
Raymond James
55 USD
Upside 55%
6 months ago
Jun 17, 2024
Piper Sandler Reiterates Overweight Rating on Agios Pharma (AGIO)
StreetInsider
Gregory Renza
RBC Capital
53 USD
Upside 50%
6 months ago
Jun 3, 2024
Agios Pharmaceuticals price target raised to $53 from $44 at RBC Capital
TheFly
Chris Raymond
Raymond James
45 USD
Upside 27%
6 months ago
May 28, 2024
Piper Sandler Reiterates Overweight Rating on Agios Pharma (AGIO)
StreetInsider
Unknown Analyst
Piper Sandler
41 USD
Upside 16%
1 year ago
Feb 3, 2023
Piper Sandler Initiates Coverage On Agios Pharmaceuticals with Overweight Rating, Announces Price Target of $41
Benzinga
Show More Price Targets
Show Less Price Targets
Danielle Brill
Raymond James
Price Target 51 USD
Upside/Downside 44%
View Source
Andrew Berens
Leerink Partners
Price Target 56 USD
Upside/Downside 58%
View Source
Chris Raymond
Raymond James
Price Target 56 USD
Upside/Downside 58%
View Source
Chris Raymond
Raymond James
Price Target 55 USD
Upside/Downside 55%
View Source
Gregory Renza
RBC Capital
Price Target 53 USD
Upside/Downside 50%
View Source
Chris Raymond
Raymond James
Price Target 45 USD
Upside/Downside 27%
View Source
Unknown Analyst
Piper Sandler
Price Target 41 USD
Upside/Downside 16%
View Source
Show More Price Targets
Show Less Price Targets
Agios Pharmaceuticals Inc Competitors:
Price Targets
CVAC
CureVac NV
174% Upside
4593
Healios KK
119% Upside
DYAI
Dyadic International Inc
425% Upside
HALO
Halozyme Therapeutics Inc
36% Upside
VYGR
Voyager Therapeutics Inc
203% Upside
EXAI
Exscientia PLC
13% Upside
RLAY
Relay Therapeutics Inc
439% Upside
298380
ABL Bio Inc
85% Upside

Revenue
Forecast

Revenue Estimate
Agios Pharmaceuticals Inc

For the last 8 years the compound annual growth rate for Agios Pharmaceuticals Inc's revenue is -9%. The projected CAGR for the next 4 years is 98%.

-9%
Past Growth
98%
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Agios Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Miss

Net Income
Forecast

Net Income Estimate
Agios Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is AGIO's stock price target?
Price Target
56.1 USD

According to Wall Street analysts, the average 1-year price target for AGIO is 56.1 USD with a low forecast of 51.51 USD and a high forecast of 59.85 USD.

What is Agios Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
98%

For the last 8 years the compound annual growth rate for Agios Pharmaceuticals Inc's revenue is -9%. The projected CAGR for the next 4 years is 98%.

Back to Top